CY1115938T1 - Νεα συνθεση για αυξηση της bio-διαθεσιμοτητας της νεουρτουρινης (neurturin) - Google Patents

Νεα συνθεση για αυξηση της bio-διαθεσιμοτητας της νεουρτουρινης (neurturin)

Info

Publication number
CY1115938T1
CY1115938T1 CY20151100013T CY151100013T CY1115938T1 CY 1115938 T1 CY1115938 T1 CY 1115938T1 CY 20151100013 T CY20151100013 T CY 20151100013T CY 151100013 T CY151100013 T CY 151100013T CY 1115938 T1 CY1115938 T1 CY 1115938T1
Authority
CY
Cyprus
Prior art keywords
neurturin
bio
availability
increasing
new composition
Prior art date
Application number
CY20151100013T
Other languages
English (en)
Inventor
Friedrich Harder
Matthias Austin
Original Assignee
Evotec International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec International Gmbh filed Critical Evotec International Gmbh
Publication of CY1115938T1 publication Critical patent/CY1115938T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με συνθέσεις με παράγοντες ανάπτυξης πρωτεΐνης, ειδικότερα νεουρτουρίνης (neurturin) σαν δραστικών συστατικών και πολύ-ανιονικών εκδόχων χαμηλού μοριακού βάρους που έχουν αυξημένη βίο-διαθεσιμότητα.
CY20151100013T 2006-06-26 2015-01-07 Νεα συνθεση για αυξηση της bio-διαθεσιμοτητας της νεουρτουρινης (neurturin) CY1115938T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06013135A EP1872790A1 (en) 2006-06-26 2006-06-26 New formulation for increasing bioavailability of neurturin
EP07764869.9A EP2040736B1 (en) 2006-06-26 2007-06-26 New formulation for increasing bioavailability of neurturin

Publications (1)

Publication Number Publication Date
CY1115938T1 true CY1115938T1 (el) 2017-01-25

Family

ID=37440830

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100013T CY1115938T1 (el) 2006-06-26 2015-01-07 Νεα συνθεση για αυξηση της bio-διαθεσιμοτητας της νεουρτουρινης (neurturin)

Country Status (9)

Country Link
US (3) US20090258829A1 (el)
EP (3) EP1872790A1 (el)
CY (1) CY1115938T1 (el)
DK (1) DK2040736T3 (el)
ES (1) ES2527093T3 (el)
PL (1) PL2040736T3 (el)
PT (1) PT2040736E (el)
SI (1) SI2040736T1 (el)
WO (1) WO2008000447A1 (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050222070A1 (en) 2002-05-29 2005-10-06 Develogen Aktiengesellschaft Fuer Entwicklungsbiologische Forschung Pancreas-specific proteins
ES2329583T3 (es) 2003-11-27 2009-11-27 Develogen Aktiengesellschaft Metodo para prevenir y tratar la diabetes con neurturina.
JP2011503019A (ja) * 2007-11-05 2011-01-27 デベローゲン アクティーゲンゲゼルゲゼルシャフト 薬学的使用のための新規のニュールツリン複合体
US8445432B2 (en) 2009-10-30 2013-05-21 Ntf Therapeutics Inc Neurturin molecules
US9127083B2 (en) 2009-10-30 2015-09-08 Ntf Therapeutics, Inc. Neurturin molecules
CN106727289A (zh) * 2016-11-11 2017-05-31 上海雅本化学有限公司 一种磺达肝癸钠组合物注射液及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
EP1241258A3 (en) 1989-10-16 2003-12-10 Amgen Inc. Stem cell factor
AU1052492A (en) * 1991-01-31 1992-08-06 Farmitalia Carlo Erba S.R.L. Synergistic composition comprising a fibroblast growth factor and a sulfated polylsaccharide, for use as antiviral agent
HU220795B1 (hu) 1991-09-20 2002-05-28 Amgen Inc. Gliasejtvonal-eredetű neurotróf faktorfehérjék, továbbá berendezések és gyógyászati készítmények idegsejtkárosodás megelőzésére és kezelésére
US5464815A (en) * 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
US5739307A (en) 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US6043221A (en) 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product
FR2812551B1 (fr) * 2000-08-07 2003-03-28 Virsol Forme pharmaceutique comprenant un materiau support a base de methylidene malonate et un facteur de regulation cellulaire
JP2005503141A (ja) 2001-07-24 2005-02-03 ノボ　ノルディスク　アクティーゼルスカブ アシル化ポリペプチドを作出するための方法
JP2005527614A (ja) 2002-05-29 2005-09-15 デヴェロゲン アクチエンゲゼルシャフト フュア エントヴィックルングスビオローギッシェ フォルシュング 膵臓特異性タンパク質
ES2329583T3 (es) * 2003-11-27 2009-11-27 Develogen Aktiengesellschaft Metodo para prevenir y tratar la diabetes con neurturina.
BRPI0710800A2 (pt) * 2006-04-25 2012-01-17 Univ California administração de fatores de crescimento para o tratamento de distúrbios de snc

Also Published As

Publication number Publication date
WO2008000447A1 (en) 2008-01-03
EP2371379A3 (en) 2012-12-26
PL2040736T3 (pl) 2015-04-30
US20130053313A1 (en) 2013-02-28
EP2371379A2 (en) 2011-10-05
US20090258829A1 (en) 2009-10-15
SI2040736T1 (sl) 2015-03-31
DK2040736T3 (en) 2015-01-12
PT2040736E (pt) 2014-12-31
EP2040736B1 (en) 2014-12-10
US20140162948A1 (en) 2014-06-12
EP2040736A1 (en) 2009-04-01
EP1872790A1 (en) 2008-01-02
ES2527093T3 (es) 2015-01-20

Similar Documents

Publication Publication Date Title
CY1115938T1 (el) Νεα συνθεση για αυξηση της bio-διαθεσιμοτητας της νεουρτουρινης (neurturin)
CY1119595T1 (el) Χορηγουμενες απο το στομα συνθεσεις καθυστερημενης αποδεσμευσης που περιεχουν αμορφο cddo-me
WO2008073448A3 (en) Pharmaceutical formulations and methods for making the same
PH12015500773A1 (en) Methods and compositions for live attenuated viruses
EP3381445A3 (en) Aqueous formulation of antibody stablised by antioxidants for parenteral administration
EA200870219A1 (ru) Стабилизированные сукцинатом витамина е фармацевтические композиции, способы их получения и применения
TW200806317A (en) Methods for reducing protein aggregation
CY1111354T1 (el) Συστασεις αναστολεα ddp iv
BRPI0516323A (pt) construtos de rna
WO2010048275A3 (en) Lyophilized recombinant vwf formulations
CY1113267T1 (el) Παραγωγα θειοφαινιου ως αγωνιστες των υποδοσεων s1p1/edg1
WO2008036932A3 (en) Compositions and methods comprising boswellia species
IS8609A (is) Endurfelling prótína af gerð ummyndandi beta vaxtarþátta
BRPI0513332A (pt) formulação de interferon peguilado estável
MX2008004734A (es) Composicion rica en leucina.
EA200701029A1 (ru) Новая композиция для облегчения человеческих родов
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
EA200800698A1 (ru) Способ стабилизации фармацевтических форм для введения, включающих микроорганизмы
ECSP099536A (es) Métodos y formulaciones para biodisponibilidad mejorada de antiprogestinas
EA201070484A1 (ru) Новые конъюгаты нейртурина для фармацевтического применения
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
CY1110213T1 (el) Παραγωγα αζολοπυριδιν-2-ονης ως αναστολεις λιπασων και φωσφολιπασων
BRPI0414008B8 (pt) compostos que se ligam a um receptor de trombopoietina, composições e métodos in vitro para ativação de um receptor de trombopoietina em uma célula
NO20065791L (no) Asyklovir-formuleringer